Search

Displaying results 1571 - 1580 of 10000 in total
  1. Drug

    Doripenem

    go.drugbank.com/drugs/DB06211
    ApprovedWithdrawn

    Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. … In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates

    Products: REDIDOR 500 MG /VIAL, DOREXTRA® DORIPENEM 500 MG
  2. Drug

    Raxtozinameran

    go.drugbank.com/drugs/DB18228
    ApprovedInvestigational

    [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272] … It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions

    Synonyms: RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptideProducts: COMIRNATY® VACUNA DE ARNM CONTRA COVID-19
  3. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.

    Products: SEGOL 1 MG/ML DAMLA, ÇÖZELTİ, 50 ML, Hydergine Tablets, 1mg
  4. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.

    Mixtures: OPSYNVI® (MACITENTAN/TADALAFILO) 10MG/40 MG TABLETAS RECUBIERTASProducts: MACITENT® 10 MG, MACITENTAN 10 MG
  5. Drug

    Levomethadone

    go.drugbank.com/drugs/DB13515
    Investigational

    Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive DisordersProducts: L-Polamidon 20 mg Tabletten, Levo-Methasan 20 mg-Tabletten
  6. Drug

    Colistin

    go.drugbank.com/drugs/DB00803
    ApprovedInvestigational

    It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.

    Synonyms: Polymyxin EProducts: APSASOL COLISTIN Powder 100 mg/g, Rican Premix Powder 1,900 IU/mg
  7. Drug

    Ubidecarenone

    go.drugbank.com/drugs/DB09270
    ApprovedInvestigationalNutraceutical

    [A31413] The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. … [A7874] It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation.

    Mixtures: Coen.q10w.vit.c and E Beta-car.se Cu Zn Mn, Coq10 With E400 IuProducts: Now Coq10 100 mg, Coenzyme Q10 100 mg
  8. Drug

    Ramelteon

    go.drugbank.com/drugs/DB00980
    ApprovedInvestigational

    Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN).

    Products: RAMELDA 8 MG FILM KAPLI TABLET,30 ADET, ROZEREST 8 MG FİLM KAPLI TABLET, 10 ADET
  9. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. Diosmin is a bio...

    International brands: Ven-DetrexMixtures: DAFLON TABLET 500 mg, VENOMAX ® 500 MG TABLETAS
  10. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    This modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].

    Products: ESPEROCT® 2000 UI, ESPEROCT 2000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET